Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
This study offers longitudinal insight into the impact of three SARS-CoV-2 vaccinations on humoral and cellular immunity in patients with solid cancers, patients with hematologic malignancies, and persons without cancer. For all cohorts, virus-neutralizing immunity was significantly depleted over a...
Gespeichert in:
| Veröffentlicht in: | Cancer research communications 2022-11, Vol.2 (11), p.1449-1461 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1461 |
|---|---|
| container_issue | 11 |
| container_start_page | 1449 |
| container_title | Cancer research communications |
| container_volume | 2 |
| creator | McKenzie, Duncan R Graham, Rosalind Lechmere, Thomas Domingo-Vila, Clara Alaguthurai, Thanussuyah Arman, Celeste Pollock, Emily Gousis, Charalampos Kakkassery, Helen Carpenter, Esme Kurshan, Ashwini Vidler, Jennifer Kulasekararaj, Austin Patten, Piers North, Bernard V Tree, Timothy Doores, Katie J Hayday, Adrian C Irshad, Sheeba |
| description | This study offers longitudinal insight into the impact of three SARS-CoV-2 vaccinations on humoral and cellular immunity in patients with solid cancers, patients with hematologic malignancies, and persons without cancer. For all cohorts, virus-neutralizing immunity was significantly depleted over a period of up to 9 months following the second vaccine dose, the one striking exception being IL2 production by SARS-CoV-2 antigen-specific T cells. Immunity was restored by the third vaccine dose, except in a substantial number of patients with hematologic malignancy, for whom both cancer type and treatment schedule were associated with nonresponse. Thus, whereas most patients with myelodysplastic syndrome were conspicuously good responders, some patients with other hematologic malignancies receiving cancer therapies within 2 weeks of vaccination showed no seroconversion despite three vaccine doses. Moreover, SARS-CoV-2 exposure during the course of the study neither prevented immunity waning, even in healthy controls, nor guaranteed vaccine responsiveness. These data offer real-world human immunologic insights that can inform health policy for patients with cancer. |
| doi_str_mv | 10.1158/2767-9764.CRC-22-0298 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7614214</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2780063644</sourcerecordid><originalsourceid>FETCH-LOGICAL-c341t-1d85e7bc3ffa3fcb1802ba92db9b571e70aa678e8bf363d64fa9087e03f0b183</originalsourceid><addsrcrecordid>eNpVkV1LwzAUhoMobqg_QcmlN535aJP0RpjFLxgoU_QypG3iKm0zk1bx35swHfMqIe973nNyHgBOMZphnIkLwhlPcs7SWbEsEkISRHKxB6bb9_2d-wSceP-OECKcpxmjh2BCmSApIWgKuitr_dD0b9Aa-Kp6XcO7sbNOtVD1NSx0246tcnCp_dr2Xns4WPg0Xz4lhX1JCHxRrlH94GN5YftKux7OOxvyHtXQ6Kh8NcMKFipqx-DAqNbrk9_zCDzfXD8Xd8ni4fa-mC-SiqZ4SHAtMs3LihqjqKlKLBApVU7qMi8zjjVHSjEutCgNZbRmqVE5ElwjalAw0yNwuYldj2Wn6yqMET4k167plPuWVjXyv9I3K_lmPyVnOCU4DQHnvwHOfozaD7JrfBV2ERZkRy8JFwgxytJozTbWylnvnTbbNhjJCEtGEDKCkAGWJERGWKHubHfGbdUfGvoD5O6Rbg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2780063644</pqid></control><display><type>article</type><title>Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>McKenzie, Duncan R ; Graham, Rosalind ; Lechmere, Thomas ; Domingo-Vila, Clara ; Alaguthurai, Thanussuyah ; Arman, Celeste ; Pollock, Emily ; Gousis, Charalampos ; Kakkassery, Helen ; Carpenter, Esme ; Kurshan, Ashwini ; Vidler, Jennifer ; Kulasekararaj, Austin ; Patten, Piers ; North, Bernard V ; Tree, Timothy ; Doores, Katie J ; Hayday, Adrian C ; Irshad, Sheeba</creator><creatorcontrib>McKenzie, Duncan R ; Graham, Rosalind ; Lechmere, Thomas ; Domingo-Vila, Clara ; Alaguthurai, Thanussuyah ; Arman, Celeste ; Pollock, Emily ; Gousis, Charalampos ; Kakkassery, Helen ; Carpenter, Esme ; Kurshan, Ashwini ; Vidler, Jennifer ; Kulasekararaj, Austin ; Patten, Piers ; North, Bernard V ; Tree, Timothy ; Doores, Katie J ; Hayday, Adrian C ; Irshad, Sheeba</creatorcontrib><description>This study offers longitudinal insight into the impact of three SARS-CoV-2 vaccinations on humoral and cellular immunity in patients with solid cancers, patients with hematologic malignancies, and persons without cancer. For all cohorts, virus-neutralizing immunity was significantly depleted over a period of up to 9 months following the second vaccine dose, the one striking exception being IL2 production by SARS-CoV-2 antigen-specific T cells. Immunity was restored by the third vaccine dose, except in a substantial number of patients with hematologic malignancy, for whom both cancer type and treatment schedule were associated with nonresponse. Thus, whereas most patients with myelodysplastic syndrome were conspicuously good responders, some patients with other hematologic malignancies receiving cancer therapies within 2 weeks of vaccination showed no seroconversion despite three vaccine doses. Moreover, SARS-CoV-2 exposure during the course of the study neither prevented immunity waning, even in healthy controls, nor guaranteed vaccine responsiveness. These data offer real-world human immunologic insights that can inform health policy for patients with cancer.</description><identifier>ISSN: 2767-9764</identifier><identifier>EISSN: 2767-9764</identifier><identifier>DOI: 10.1158/2767-9764.CRC-22-0298</identifier><identifier>PMID: 36824220</identifier><language>eng</language><publisher>United States</publisher><subject>COVID-19 ; Hematologic Neoplasms ; Humans ; Neoplasms ; SARS-CoV-2 - genetics</subject><ispartof>Cancer research communications, 2022-11, Vol.2 (11), p.1449-1461</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c341t-1d85e7bc3ffa3fcb1802ba92db9b571e70aa678e8bf363d64fa9087e03f0b183</citedby><cites>FETCH-LOGICAL-c341t-1d85e7bc3ffa3fcb1802ba92db9b571e70aa678e8bf363d64fa9087e03f0b183</cites><orcidid>0000-0002-7131-5603 ; 0000-0002-7297-4205 ; 0000-0003-0961-8846 ; 0000-0002-8080-8274 ; 0000-0003-3180-3570 ; 0000-0002-4747-4794 ; 0000-0002-5299-2342 ; 0000-0002-5507-1725 ; 0000-0002-1086-4684 ; 0000-0003-2996-3014 ; 0000-0001-9279-6672 ; 0000-0002-4453-8078 ; 0000-0002-6973-5377 ; 0000-0002-9656-6038 ; 0000-0001-9504-2294 ; 0000-0002-9495-5793 ; 0000-0003-3320-3034 ; 0000-0002-4419-7162 ; 0000-0001-7205-978X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614214/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614214/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36824220$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McKenzie, Duncan R</creatorcontrib><creatorcontrib>Graham, Rosalind</creatorcontrib><creatorcontrib>Lechmere, Thomas</creatorcontrib><creatorcontrib>Domingo-Vila, Clara</creatorcontrib><creatorcontrib>Alaguthurai, Thanussuyah</creatorcontrib><creatorcontrib>Arman, Celeste</creatorcontrib><creatorcontrib>Pollock, Emily</creatorcontrib><creatorcontrib>Gousis, Charalampos</creatorcontrib><creatorcontrib>Kakkassery, Helen</creatorcontrib><creatorcontrib>Carpenter, Esme</creatorcontrib><creatorcontrib>Kurshan, Ashwini</creatorcontrib><creatorcontrib>Vidler, Jennifer</creatorcontrib><creatorcontrib>Kulasekararaj, Austin</creatorcontrib><creatorcontrib>Patten, Piers</creatorcontrib><creatorcontrib>North, Bernard V</creatorcontrib><creatorcontrib>Tree, Timothy</creatorcontrib><creatorcontrib>Doores, Katie J</creatorcontrib><creatorcontrib>Hayday, Adrian C</creatorcontrib><creatorcontrib>Irshad, Sheeba</creatorcontrib><title>Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer</title><title>Cancer research communications</title><addtitle>Cancer Res Commun</addtitle><description>This study offers longitudinal insight into the impact of three SARS-CoV-2 vaccinations on humoral and cellular immunity in patients with solid cancers, patients with hematologic malignancies, and persons without cancer. For all cohorts, virus-neutralizing immunity was significantly depleted over a period of up to 9 months following the second vaccine dose, the one striking exception being IL2 production by SARS-CoV-2 antigen-specific T cells. Immunity was restored by the third vaccine dose, except in a substantial number of patients with hematologic malignancy, for whom both cancer type and treatment schedule were associated with nonresponse. Thus, whereas most patients with myelodysplastic syndrome were conspicuously good responders, some patients with other hematologic malignancies receiving cancer therapies within 2 weeks of vaccination showed no seroconversion despite three vaccine doses. Moreover, SARS-CoV-2 exposure during the course of the study neither prevented immunity waning, even in healthy controls, nor guaranteed vaccine responsiveness. These data offer real-world human immunologic insights that can inform health policy for patients with cancer.</description><subject>COVID-19</subject><subject>Hematologic Neoplasms</subject><subject>Humans</subject><subject>Neoplasms</subject><subject>SARS-CoV-2 - genetics</subject><issn>2767-9764</issn><issn>2767-9764</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkV1LwzAUhoMobqg_QcmlN535aJP0RpjFLxgoU_QypG3iKm0zk1bx35swHfMqIe973nNyHgBOMZphnIkLwhlPcs7SWbEsEkISRHKxB6bb9_2d-wSceP-OECKcpxmjh2BCmSApIWgKuitr_dD0b9Aa-Kp6XcO7sbNOtVD1NSx0246tcnCp_dr2Xns4WPg0Xz4lhX1JCHxRrlH94GN5YftKux7OOxvyHtXQ6Kh8NcMKFipqx-DAqNbrk9_zCDzfXD8Xd8ni4fa-mC-SiqZ4SHAtMs3LihqjqKlKLBApVU7qMi8zjjVHSjEutCgNZbRmqVE5ElwjalAw0yNwuYldj2Wn6yqMET4k167plPuWVjXyv9I3K_lmPyVnOCU4DQHnvwHOfozaD7JrfBV2ERZkRy8JFwgxytJozTbWylnvnTbbNhjJCEtGEDKCkAGWJERGWKHubHfGbdUfGvoD5O6Rbg</recordid><startdate>20221117</startdate><enddate>20221117</enddate><creator>McKenzie, Duncan R</creator><creator>Graham, Rosalind</creator><creator>Lechmere, Thomas</creator><creator>Domingo-Vila, Clara</creator><creator>Alaguthurai, Thanussuyah</creator><creator>Arman, Celeste</creator><creator>Pollock, Emily</creator><creator>Gousis, Charalampos</creator><creator>Kakkassery, Helen</creator><creator>Carpenter, Esme</creator><creator>Kurshan, Ashwini</creator><creator>Vidler, Jennifer</creator><creator>Kulasekararaj, Austin</creator><creator>Patten, Piers</creator><creator>North, Bernard V</creator><creator>Tree, Timothy</creator><creator>Doores, Katie J</creator><creator>Hayday, Adrian C</creator><creator>Irshad, Sheeba</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7131-5603</orcidid><orcidid>https://orcid.org/0000-0002-7297-4205</orcidid><orcidid>https://orcid.org/0000-0003-0961-8846</orcidid><orcidid>https://orcid.org/0000-0002-8080-8274</orcidid><orcidid>https://orcid.org/0000-0003-3180-3570</orcidid><orcidid>https://orcid.org/0000-0002-4747-4794</orcidid><orcidid>https://orcid.org/0000-0002-5299-2342</orcidid><orcidid>https://orcid.org/0000-0002-5507-1725</orcidid><orcidid>https://orcid.org/0000-0002-1086-4684</orcidid><orcidid>https://orcid.org/0000-0003-2996-3014</orcidid><orcidid>https://orcid.org/0000-0001-9279-6672</orcidid><orcidid>https://orcid.org/0000-0002-4453-8078</orcidid><orcidid>https://orcid.org/0000-0002-6973-5377</orcidid><orcidid>https://orcid.org/0000-0002-9656-6038</orcidid><orcidid>https://orcid.org/0000-0001-9504-2294</orcidid><orcidid>https://orcid.org/0000-0002-9495-5793</orcidid><orcidid>https://orcid.org/0000-0003-3320-3034</orcidid><orcidid>https://orcid.org/0000-0002-4419-7162</orcidid><orcidid>https://orcid.org/0000-0001-7205-978X</orcidid></search><sort><creationdate>20221117</creationdate><title>Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer</title><author>McKenzie, Duncan R ; Graham, Rosalind ; Lechmere, Thomas ; Domingo-Vila, Clara ; Alaguthurai, Thanussuyah ; Arman, Celeste ; Pollock, Emily ; Gousis, Charalampos ; Kakkassery, Helen ; Carpenter, Esme ; Kurshan, Ashwini ; Vidler, Jennifer ; Kulasekararaj, Austin ; Patten, Piers ; North, Bernard V ; Tree, Timothy ; Doores, Katie J ; Hayday, Adrian C ; Irshad, Sheeba</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c341t-1d85e7bc3ffa3fcb1802ba92db9b571e70aa678e8bf363d64fa9087e03f0b183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>COVID-19</topic><topic>Hematologic Neoplasms</topic><topic>Humans</topic><topic>Neoplasms</topic><topic>SARS-CoV-2 - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McKenzie, Duncan R</creatorcontrib><creatorcontrib>Graham, Rosalind</creatorcontrib><creatorcontrib>Lechmere, Thomas</creatorcontrib><creatorcontrib>Domingo-Vila, Clara</creatorcontrib><creatorcontrib>Alaguthurai, Thanussuyah</creatorcontrib><creatorcontrib>Arman, Celeste</creatorcontrib><creatorcontrib>Pollock, Emily</creatorcontrib><creatorcontrib>Gousis, Charalampos</creatorcontrib><creatorcontrib>Kakkassery, Helen</creatorcontrib><creatorcontrib>Carpenter, Esme</creatorcontrib><creatorcontrib>Kurshan, Ashwini</creatorcontrib><creatorcontrib>Vidler, Jennifer</creatorcontrib><creatorcontrib>Kulasekararaj, Austin</creatorcontrib><creatorcontrib>Patten, Piers</creatorcontrib><creatorcontrib>North, Bernard V</creatorcontrib><creatorcontrib>Tree, Timothy</creatorcontrib><creatorcontrib>Doores, Katie J</creatorcontrib><creatorcontrib>Hayday, Adrian C</creatorcontrib><creatorcontrib>Irshad, Sheeba</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer research communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McKenzie, Duncan R</au><au>Graham, Rosalind</au><au>Lechmere, Thomas</au><au>Domingo-Vila, Clara</au><au>Alaguthurai, Thanussuyah</au><au>Arman, Celeste</au><au>Pollock, Emily</au><au>Gousis, Charalampos</au><au>Kakkassery, Helen</au><au>Carpenter, Esme</au><au>Kurshan, Ashwini</au><au>Vidler, Jennifer</au><au>Kulasekararaj, Austin</au><au>Patten, Piers</au><au>North, Bernard V</au><au>Tree, Timothy</au><au>Doores, Katie J</au><au>Hayday, Adrian C</au><au>Irshad, Sheeba</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer</atitle><jtitle>Cancer research communications</jtitle><addtitle>Cancer Res Commun</addtitle><date>2022-11-17</date><risdate>2022</risdate><volume>2</volume><issue>11</issue><spage>1449</spage><epage>1461</epage><pages>1449-1461</pages><issn>2767-9764</issn><eissn>2767-9764</eissn><abstract>This study offers longitudinal insight into the impact of three SARS-CoV-2 vaccinations on humoral and cellular immunity in patients with solid cancers, patients with hematologic malignancies, and persons without cancer. For all cohorts, virus-neutralizing immunity was significantly depleted over a period of up to 9 months following the second vaccine dose, the one striking exception being IL2 production by SARS-CoV-2 antigen-specific T cells. Immunity was restored by the third vaccine dose, except in a substantial number of patients with hematologic malignancy, for whom both cancer type and treatment schedule were associated with nonresponse. Thus, whereas most patients with myelodysplastic syndrome were conspicuously good responders, some patients with other hematologic malignancies receiving cancer therapies within 2 weeks of vaccination showed no seroconversion despite three vaccine doses. Moreover, SARS-CoV-2 exposure during the course of the study neither prevented immunity waning, even in healthy controls, nor guaranteed vaccine responsiveness. These data offer real-world human immunologic insights that can inform health policy for patients with cancer.</abstract><cop>United States</cop><pmid>36824220</pmid><doi>10.1158/2767-9764.CRC-22-0298</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-7131-5603</orcidid><orcidid>https://orcid.org/0000-0002-7297-4205</orcidid><orcidid>https://orcid.org/0000-0003-0961-8846</orcidid><orcidid>https://orcid.org/0000-0002-8080-8274</orcidid><orcidid>https://orcid.org/0000-0003-3180-3570</orcidid><orcidid>https://orcid.org/0000-0002-4747-4794</orcidid><orcidid>https://orcid.org/0000-0002-5299-2342</orcidid><orcidid>https://orcid.org/0000-0002-5507-1725</orcidid><orcidid>https://orcid.org/0000-0002-1086-4684</orcidid><orcidid>https://orcid.org/0000-0003-2996-3014</orcidid><orcidid>https://orcid.org/0000-0001-9279-6672</orcidid><orcidid>https://orcid.org/0000-0002-4453-8078</orcidid><orcidid>https://orcid.org/0000-0002-6973-5377</orcidid><orcidid>https://orcid.org/0000-0002-9656-6038</orcidid><orcidid>https://orcid.org/0000-0001-9504-2294</orcidid><orcidid>https://orcid.org/0000-0002-9495-5793</orcidid><orcidid>https://orcid.org/0000-0003-3320-3034</orcidid><orcidid>https://orcid.org/0000-0002-4419-7162</orcidid><orcidid>https://orcid.org/0000-0001-7205-978X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2767-9764 |
| ispartof | Cancer research communications, 2022-11, Vol.2 (11), p.1449-1461 |
| issn | 2767-9764 2767-9764 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7614214 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | COVID-19 Hematologic Neoplasms Humans Neoplasms SARS-CoV-2 - genetics |
| title | Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T09%3A34%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Boosting%20of%20Waned%20Humoral%20and%20Cellular%20Responses%20to%20SARS-CoV-2%20Variants%20of%20Concern%20Among%20Patients%20with%20Cancer&rft.jtitle=Cancer%20research%20communications&rft.au=McKenzie,%20Duncan%20R&rft.date=2022-11-17&rft.volume=2&rft.issue=11&rft.spage=1449&rft.epage=1461&rft.pages=1449-1461&rft.issn=2767-9764&rft.eissn=2767-9764&rft_id=info:doi/10.1158/2767-9764.CRC-22-0298&rft_dat=%3Cproquest_pubme%3E2780063644%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2780063644&rft_id=info:pmid/36824220&rfr_iscdi=true |